| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 338.598.654 $ | +44.171.230 $ | +25,9 % | 13 | 296.028.146 $ | +296.028.146 $ | 12 | |||||
| PFIZER INC | PFE | → 0 | Neutral | 44.757.891 $ | -6.093.935 $ | -12,0 % | 1 | 50.851.826 $ | +50.851.826 $ | 1 | |
| REGENERON PHARMACEUTICALS, INC. | REGN | → 0 | Stark | 34.614.272 $ | -5.847.153 $ | -14,5 % | 1 | 40.461.425 $ | +40.461.425 $ | 1 | |
| BioNTech SE | BNTX | → 0 | Neutral | 27.113.288 $ | -8.226.475 $ | -23,3 % | 1 | 35.339.763 $ | +35.339.763 $ | 1 | |
| Royalty Pharma plc | RPRX | → 0 | Schwach | 24.944.832 $ | -7.537.884 $ | -23,2 % | 1 | 32.482.716 $ | +32.482.716 $ | 1 | |
| ARGENX SE | ARGX | → 0 | Stark | 25.591.611 $ | -4.417.690 $ | -14,7 % | 1 | 30.009.301 $ | +30.009.301 $ | 1 | |
| INSMED Inc | INSM | → 0 | Neutral | 29.852.538 $ | +29.852.538 $ | 1 | |||||
| IONIS PHARMACEUTICALS INC | IONS | → 0 | Schwach | 29.052.546 $ | +10.186.631 $ | +54,0 % | 1 | 18.865.915 $ | +18.865.915 $ | 1 | |
| Natera, Inc. | NTRA | → 0 | Neutral | 28.791.760 $ | +10.773.831 $ | +59,8 % | 1 | 18.017.929 $ | +18.017.929 $ | 1 | |
| ELI LILLY & Co | LLY | → 0 | Neutral | 25.090.406 $ | +16.163.039 $ | +181,1 % | 1 | 8.927.367 $ | +8.927.367 $ | 1 | |
| Roivant Sciences Ltd. | ROIV | → 0 | Schwach | 24.193.125 $ | +1.879.058 $ | +8,4 % | 1 | 22.314.067 $ | +22.314.067 $ | 1 | |
| Legend Biotech Corp | LEGN | → 0 | Schwach | 23.783.791 $ | +811.829 $ | +3,5 % | 1 | 22.971.962 $ | +22.971.962 $ | 1 | |
| Mineralys Therapeutics, Inc. | MLYS | → 0 | Neutral | 12.113.375 $ | +4.468.959 $ | +58,5 % | 1 | 7.644.416 $ | +7.644.416 $ | 1 | |
| Abivax S.A. | ABVX | → 0 | Schwach | 8.699.219 $ | +2.158.482 $ | +33,0 % | 1 | ||||
| Viridian Therapeutics, Inc.\DE | VRDN | → 0 | Schwach | 8.141.459 $ | +8.141.459 $ | 1 | |||||
| 338.598.654 $ | +44.171.230 $ | +25,9 % | 13 | 296.028.146 $ | +296.028.146 $ | 12 | |||||